Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY)

Tipranks - Tipranks - Tue Apr 7, 2:58AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY).

Easter Sale - 70% Off TipRanks

Viridian Therapeutics (VRDN)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Viridian Therapeutics today and set a price target of $22.00. The company’s shares closed last Thursday at $18.84.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 17.3% and a 48.1% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Rapport Therapeutics, Inc., Praxis Precision Medicines, and Neumora Therapeutics, Inc. ;'>

Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $36.17, implying a 94.9% upside from current levels. In a report issued on March 23, Wedbush also maintained a Buy rating on the stock with a $44.00 price target.

See today’s best-performing stocks on TipRanks >>

Bristol-Myers Squibb (BMY)

In a report issued on April 3, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb. The company’s shares closed last Thursday at $59.60, close to its 52-week high of $63.33.

According to TipRanks.com, Breen is a 4-star analyst with an average return of 19.4% and a 84.1% success rate. Breen covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Merck & Company, and Eli Lilly & Co. ;'>

Currently, the analyst consensus on Bristol-Myers Squibb is a Moderate Buy with an average price target of $62.94, implying a 4.5% upside from current levels. In a report issued on April 2, Wells Fargo also assigned a Hold rating to the stock with a $60.00 price target.

Read More on VRDN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).